Genzyme — Merger or Acquisition (February 2011)
13 slides from Genzyme's merger presentation, Feb 16, 2011
Slide 1: Sanofi-aventis Town hall meeting
Sanofi-aventis Town hall meeting February 16 th , 2011
Slide 2: Forward-Looking Statements
Forward-Looking Statements Important Information about this Transaction This communication is neither an offer to purchase nor a solicitation of any offer to sell any securities. In connection with the proposed transaction, sanofi-aventis will file an amended tender offer statement and a registratio
Slide 3: “ sanofi ave
“ sanofi ave
Slide 4: Sanofi-aventis - A world leader
30,384 Sanofi-aventis - A world leader € 30,384 m 2010 NET SALES-GROSS OF 3,7% COMPARED WITH 2009 ON A REPORTED BASIS 100,000 More than 100,000 EMPLOYEES WORLDWIDE ONE OF THE LARGEST PHARMACEUTICAL GROUPS IN THE WORLD
Slide 5: Core growth platforms
- A global sustainable healthcare partner focused on patients’ needs - Recognised for our ability to transform scientific innovation into hope and solutions for patients Achieving our ambition through core growth platforms Growth platforms Diabetes Vaccines Emerging Markets Consumer Health Care Inno
Slide 6: Our response to health issues
Diabetes Oncology Cardiovascular Atrial Fibrillation Vaccines Consumer Heath Care Our response to health issues
Slide 7: Our culture
Our culture CONFIDENCE INNOVATION RESPECT SOLIDARITY INTEGRITY
Slide 8: Town hall meeting
Town hall meeting February 16 th , 2011
Slide 9: General principles for working together
General principles for working together Acknowledge and recognize your unique know-how and build on your DNA Genzyme brand Greater Boston Area Listen to you, understand your business and create a collaborative spirit to take this forward together Focus on the day-to-day business and continue to addr
Slide 10: Organization for integration
Organization for integration • Chris Viehbacher (co-chair) • Belén Garijo (Integration Leader) • Jérôme Contamine (Finance) • Karen Linehan (Legal) • Roberto Pucci (HR) • Laure Thibaud (Comm.) • Philippe Luscan (IA) adhoc • Elias Zerhouni (R&D) adhoc • Sanofi-aventis and Genzyme representation to be
Slide 11: Proposed high-level organization for integration
Manufacturing Proposed high-level organization for integration HR integration support & talent management Internal/external communication Metrics Process management / guidelines Finance HR Purchasing Legal IT Real Estate Quality work streams (business assessment, strategy, integration model) Communi
Slide 12: High-level calendar
Understanding and planning Business continuity and integration country level kick off High-level calendar Q1 Q2 Q3 Q4 Legal process (tender offer, CVR registration) Feb th Merger agreement Transaction closing / Day 1 Feb 16 th Global Kick-off pre-integration Legal process Pre-integration work Integr
Slide 13: Questions & answers
Questions & answers